Clinical trials
Pancreatitis clinical trials
Below are recruiting pancreatitis clinical trials, each written for real people, not researchers. We’re tracking 1,047 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06575426RecruitingPhase 1/Phase 2
Pig pancreatic cell transplant for type 1 diabetes
This trial tests a new treatment made from pig pancreatic cells (called OPF-310) that are placed under the skin to help control blood sugar in people with type 1 diabetes. It is for those whose diabetes is difficult to manage and who have dangerous low blood sugar episodes.
Chicago, IllinoisAges 35–70 - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Duarte, CaliforniaAges 18 years+ - NCT06860984RecruitingPhase 3
Evaluating the Safety and Efficacy of Duloxetine in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis
This phase 3 trial tests duloxetine for preventing pancreatitis after ERCP in adults with normal baseline amylase/lipase and without certain comorbidities.
TantaAges 18–65 - NCT05463796Recruiting
Prevention and early detection for people at high cancer risk
This study looks at surveillance (watching closely), prevention, and early “interception” steps to lower the chance that cancer will develop or be found later. It is for people with genetic risk, past cancer treatment exposures, strong family history, or certain early pre-cancer or high-risk conditions.
Boston, MassachusettsAges Any age - NCT07440290RecruitingPhase 2/Phase 3
Dabrafenib and trametinib for BRAF V600 cancers
This trial tests two targeted drugs (dabrafenib and trametinib) for patients whose cancer has a specific change in the BRAF gene called V600. These drugs work together to block signals that help the cancer grow. The trial is for children, teenagers, and adults with many types of cancer, except for a few common ones that already have approved treatments.
BelfastAges 1 year+ - NCT05985655RecruitingPhase 1/Phase 2
Study of GTAEXS617 for advanced solid tumors
This trial tests a new drug called GTAEXS617 for adults with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT05288205RecruitingPhase 1/Phase 2
JAB-21822 plus JAB-3312 for KRAS G12C solid tumors
This Phase 1/2a trial tests two investigational pills (JAB-21822 and JAB-3312) in people with advanced solid cancers that have a KRAS G12C mutation. It’s for cases where standard treatments have failed or aren’t suitable, to see if the drugs can shrink tumors and improve outcomes.
Hefei, AnhuiAges 18 years+ - NCT07136701Recruiting
Pancreatic neuroendocrine tumor risk factors and prognosis
This study looks at how pancreatic neuroendocrine tumors behave differently in younger versus older people. It aims to find better ways to predict outcomes and guide treatment.
Jinan, ShandongAges 18–85 - NCT06058442RecruitingPhase 3
Digestive enzymes after stomach surgery trial
This trial tests whether taking a digestive enzyme supplement called NORTASE® after stomach surgery helps improve digestion and nutrition. It may help people who have had most or all of their stomach removed due to cancer or other conditions.
BornaAges 18 years+ - NCT07760012Recruiting
PET/CT scan for common solid tumors
This trial uses a new kind of PET/CT scan to take detailed pictures of solid tumors such as melanoma, liver, lung, breast, pancreatic, or ovarian cancer. The scan might help doctors find cancer more clearly.
Beijing, Beijing MunicipalityAges 18–75 - NCT04222413RecruitingPhase 1
Study of metarrestin for advanced solid tumors
This study tests an experimental drug called metarrestin for people with solid tumors that have spread or come back after standard treatment. It may help by targeting a protein involved in cancer cell growth.
Fairway, KansasAges 12–120 - NCT05706129RecruitingPhase 1/Phase 2
Testing targeted imaging and therapy for advanced solid tumors
This early-phase study tests two radioactive medicines that first help doctors see tumors and, in some parts of the study, treat them. It may help people with advanced, hard-to-remove cancers that have a specific tumor marker (CA IX).
MelbourneAges 18 years+ - NCT07756476Recruiting
Fluid treatment guided by heart response for acute pancreatitis
This study tests whether giving IV fluids based on how your heart responds can improve recovery from acute pancreatitis, compared with usual care. It may help your body handle fluids better during treatment.
Los Angeles, CaliforniaAges 18–75 - NCT07488299Recruiting
Study of acid-reducing drug in pancreatic necrosis drainage
This trial tests whether giving a type of acid-reducing drug (called a PPI) affects the outcome of endoscopic drainage for walled-off pancreatic necrosis (WON). It aims to see if the drug helps or harms recovery.
Jinan, ShandongAges 18–80 - NCT06751329RecruitingPhase 1/Phase 2
Study of DM002 for advanced solid tumors
This trial tests a new drug called DM002 for people with advanced solid tumors that have not responded to standard treatments. The drug targets two proteins (MUC1 and HER3) found on some cancer cells, and may help shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT04674267Recruiting
REACH study for older adults with GI cancer and support needs
This study looks at how to improve health and care support for people age 70 and older with gastrointestinal (GI) cancer. It may help by offering a structured way to address practical and emotional challenges that can affect aging and cancer care.
Boston, MassachusettsAges 70 years+ - NCT07127874RecruitingPhase 1
Study of PHN-012 for advanced solid tumors
This trial tests a new drug called PHN-012 for people with advanced colorectal, non-small cell lung, or pancreatic cancer who have already tried at least one standard treatment. The goal is to see if the drug can help shrink or slow tumor growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07705334RecruitingPhase 1
Study of SHY-ONC6 for advanced solid tumors
This trial tests a new drug called SHY-ONC6 that targets and breaks down cancer cells. It's for people with advanced solid tumors that haven't responded to standard treatments.
Scottsdale, ArizonaAges 18 years+ - NCT07594067RecruitingPhase 1
TCR T cells for KRAS-mutated cancers
This trial tests a new type of immune cell therapy (TCR T cells) designed to target a specific KRAS mutation (G12V) in certain advanced cancers. It may be an option for people with pancreatic, bile duct, colorectal, or lung cancer who have already tried standard treatments.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07522073RecruitingPhase 3
Chemotherapy with or without KRAS inhibitor for pancreatic cancer
This study tests whether adding a new drug called INCB161734 to standard chemotherapy helps people with advanced pancreatic cancer that has a specific genetic change (KRAS G12D mutation). You would be randomly assigned to receive either chemotherapy alone or chemotherapy plus the new drug.
Birmingham, AlabamaAges 18 years+ - NCT07227168RecruitingPhase 1
Study of STRO-004 for advanced solid tumors
This trial tests a new drug called STRO-004 for people with advanced solid tumors (cancers that have spread or come back). It aims to see if the drug is safe and effective for those who have already tried other treatments.
San Diego, CaliforniaAges 18 years+ - NCT06821503RecruitingPhase 1/Phase 2
Study of LM-108 with chemo for advanced pancreatic cancer
This trial tests a new drug called LM-108 combined with chemotherapy for people with advanced pancreatic cancer that hasn't been treated before. The goal is to see if it's safe and may help shrink tumors or stop them from growing.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06727851Enrolling by invitation
Improving ERCP quality in endoscopy
This study looks at ways to improve the quality of ERCP, a procedure that uses a flexible tube with a camera to look at the bile and pancreatic ducts. It is open to adults who can understand the study information and are having their first ERCP during this hospital stay.
WarendorfAges 18 years+ - NCT06515587Recruiting
Lewis antigen test for pancreatic cancer prognosis
This study looks at how a special blood test (Lewis antigen) combined with a standard CA19-9 test might help predict the outlook for people with pancreatic cancer. You will give a small extra blood sample and have routine follow-up tests.
Shanghai, Shanghai MunicipalityAges 18–75
Hear when a new Pancreatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatitis?
- Yes. Clin2 currently lists 1,047 recruiting pancreatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.